Jianyou Co., Ltd. (603707.SH) subsidiary obtained US FDA approval to increase production site registration for octreotide acetate injection drugs

Zhitongcaijing · 11/12/2025 09:33

Zhitong Finance App News, Jianyou Co., Ltd. (603707.SH) issued an announcement. The company's subsidiary Meitheal Pharmaceuticals, Inc. (“Meitheal”) recently received an approval letter from the US Food and Drug Administration (“US FDA”) for octreotide acetate injections, 50 mcg/mL, 100 mcg/mL, and 500 mcg/mL (ANDA: 075957) to increase production site approval for Jianyou Biochemical Pharmaceuticals in Nanjing Co., Ltd. site production.

The newly approved products will be listed and sold in the US in the near future, which is expected to have a positive impact on the company's operating performance.